U.K. and Canadian researchers found that mepolizumab, an antibody treatment, effectively reduced asthma attacks and dependence on steroids in patients with severe asthma worsened by eosinophilia, a type of persistent airway inflammation. The antibody drug works by inhibiting the production of eosinophils, white blood cells that can cause eosinophilia when in high levels, one of the researchers said.

Full Story:

Related Summaries